TARS (Tarsus Pharmaceuticals) Inventories, Finished Goods: $2.9 Mil (As of Mar. 2026)


TARS Tarsus Pharmaceuticals Inc TARS
47 GF Score
Price $62.94
GF Value $202.09
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Tarsus Pharmaceuticals Inventories, Finished Goods?

Tarsus Pharmaceuticals TARS +2.56% 47 Inventories, Finished Goods is $2.9 Mil as of Mar. 2026. GuruFocus rates TARS with a GF Score™ of 47/100 and a GF Value™ of $202.09 (Possible Value Trap). The stock has 2 warning signs investors should review.

Tarsus Pharmaceuticals's quarterly finished goods increased from Sep. 2025 ($2.8 Mil) to Dec. 2025 ($3.0 Mil) but then declined from Dec. 2025 ($3.0 Mil) to Mar. 2026 ($2.9 Mil).

Tarsus Pharmaceuticals's annual finished goods increased from Dec. 2023 ($0.2 Mil) to Dec. 2024 ($2.0 Mil) and increased from Dec. 2024 ($2.0 Mil) to Dec. 2025 ($3.0 Mil).

Tarsus Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Tarsus Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsus Pharmaceuticals Inventories, Finished Goods Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial 0.00 0.00 0.18 2.01 2.96

Tarsus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.94 2.29 2.84 2.96 2.94
TARS
47GF Score
Tarsus Pharmaceuticals Inc TARS
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tarsus Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $2.9 Mil mean?
Tarsus Pharmaceuticals (TARS) has a Inventories, Finished Goods of $2.9 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Tarsus Pharmaceuticals and its competitors.
Is Tarsus Pharmaceuticals' Inventories, Finished Goods too high?
Tarsus Pharmaceuticals' current Inventories, Finished Goods is $2.9 Mil. Overall, Tarsus Pharmaceuticals has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Inventories, Finished Goods compare to KLRA and CLDX?
Tarsus Pharmaceuticals' Inventories, Finished Goods of $2.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Tarsus Pharmaceuticals and its competitors. Tarsus Pharmaceuticals's current Inventories, Finished Goods is $2.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $202.09, compared to a current price of $62.94 — trading 68.9% below its estimated fair value. The current Inventories, Finished Goods is $2.9 Mil. Tarsus Pharmaceuticals' overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Inventories, Finished Goods is $2.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $62.94 is trading 68.9% below its estimated GF Value™ of $202.09. GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TARS:

  • Inventories, Finished Goods: $2.9 Mil
  • GF Value™: $202.09 vs. price of $62.94 (68.9% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
47GF Score

Get the complete analysis for TARS

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$62.94
Price
$202.09
GF Value